Last Updated: July 12, 2026

Patent: 3,133,861


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,133,861
Title:Attenuated live measles virus vaccine and method of production
Inventor(s):Anton J F Schwarz
Assignee: Dow Chemical Co
Application Number:US150896A
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 3,133,861: Claim Construction and US Patent Landscape Assessment

What does US 3,133,861 claim?

US 3,133,861 is a granted US patent from the early 1960s. A complete claim-by-claim analysis requires the exact claim text and the specification drawings. The provided prompt contains no claim text, no bibliographic identifiers beyond the patent number, and no link or excerpt to the official publication or assignment history. Under the operating constraints, this response cannot be produced accurately without the full, verifiable claim language and relevant document set.

What is the claim scope and how would courts likely construe it?

Accurate scope assessment depends on:

  • the independent claims’ exact wording,
  • claim dependencies and limitations,
  • the definitions used in the specification,
  • prosecution history and disclaimers, and
  • whether terms are structural, functional, or result-driven.

No claim text or prosecution record was supplied. A “comprehensive and critical analysis” that nevertheless fills in missing claim language would risk fabricating limitations and legal outcomes.

How crowded is the surrounding US patent landscape?

Landscape mapping requires a search corpus keyed to:

  • assignee/inventors,
  • CPC/USPC classes,
  • priority dates,
  • claim keywords from independent claims, and
  • cited references and examiner citations.

No cited-reference list, assignee, priority data, CPC classification, or bibliographic export was provided. Without those inputs, any statement about novelty, saturation, or obviousness likelihood would be ungrounded.

Where are the likely freedom-to-operate pinch points?

FTO pinch points are claim- and jurisdiction-specific and depend on:

  • whether the patent covers a core mechanism vs. peripheral features,
  • whether the claim limitations map onto common commercial embodiments,
  • prior art that anticipates or renders obvious each limitation, and
  • the presence of design-around pathways (alternative architectures or materials).

No claim limitations or exemplary embodiments were provided, so FTO mapping cannot be done without guessing.

What prior art arguments would matter for validity?

Validity analysis requires:

  • identification of the closest prior art references,
  • mapping each claim element to specific disclosures,
  • determining whether any missing element is supplied by another reference or by routine skill,
  • and assessing statutory subject matter and enablement for the era.

No reference list, citations, or claim elements are available in the prompt.

What does the landscape imply for enforcement leverage?

Enforcement leverage depends on:

  • surviving claim breadth after claim construction,
  • the number and strength of close prior art,
  • whether the patent is still within enforceable term and whether intervening rights or terminal disclaimers apply,
  • and whether later continuations or reissues exist.

No term/expiration or prosecution history was provided.

Key takeaways

  1. A claim-by-claim and element-by-element analysis for US 3,133,861 cannot be produced from the information in the prompt.
  2. Landscape saturation, obviousness risk, and enforceability require the exact claim text, bibliographic data, and cited references, none of which were provided.
  3. Any attempt to answer “comprehensively and critically” without the underlying claim language would risk inaccurate construction and fabricated prior-art mapping.

FAQs

1) Can you analyze US 3,133,861 claims without the claim text?

No. Claim scope and construction depend on the verbatim independent and dependent claim limitations.

2) Can you map novelty and obviousness without the cited references?

No. Validity requires element-to-reference mapping using the examiner’s citations and the closest pre-grant disclosures.

3) Can you assess US patent landscape density without search keys?

No. Landscape results require CPC/USPC classification, priority dates, assignee/inventor identifiers, and claim keywords.

4) Is enforcement leverage determined only by claim breadth?

No. It also depends on prosecution history, prior-art strength, enforceability status, and how courts construe disputed terms.

5) What is the minimum data needed to do a patent-grade analysis?

Verbatim claims (all), bibliographic fields (assignee, priority), and the list of cited references with publication details.


[1] USPTO Patent Full-Text and Image Database (USPTO PatFT). (Access required for claim text and bibliographic data for US 3,133,861).
[2] USPTO Patent Application Information Retrieval (PAIR) / Patent Center (for prosecution history if available for US 3,133,861).
[3] Google Patents (for claim text, cited references, family data for US 3,133,861).
[4] Lens.org (for bibliographic and citation context for US 3,133,861).

More… ↓

⤷  Start Trial

Details for Patent 3,133,861

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Biologicals PRIORIX measles, mumps and rubella vaccine live For Injection 125748 June 03, 2022 3,133,861 1981-11-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.